Investment House LLC Has $11.92 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Investment House LLC lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.0% during the 4th quarter, Holdings Channel reports. The firm owned 156,263 shares of the medical research company’s stock after purchasing an additional 6,043 shares during the quarter. Investment House LLC’s holdings in Edwards Lifesciences were worth $11,915,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in Edwards Lifesciences by 440.0% in the third quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after acquiring an additional 2,860,000 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $168,519,000. Nordea Investment Management AB lifted its holdings in shares of Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Edwards Lifesciences by 61.1% in the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock valued at $215,557,000 after purchasing an additional 1,179,637 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 over the last ninety days. Company insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on EW shares. Oppenheimer raised their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Citigroup boosted their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Morgan Stanley raised their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday. Finally, StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.41 during trading on Monday, hitting $86.02. 1,458,816 shares of the company’s stock traded hands, compared to its average volume of 3,814,264. The stock has a market capitalization of $51.78 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.28 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The business has a 50 day moving average of $90.28 and a 200-day moving average of $78.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.